تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
3.99 US$
+0.41 US$ · +11.45%
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
الإغلاق السابق
3.99 US$
+0.41 US$ · +11.45%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
نطاق اليوم
السعر الحالي 3.99 US$
نطاق 52 أسبوعًا
السعر الحالي 3.99 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
30
مرتفع السعر
المشاعر
60
مختلط
المخاطر
75
مخاطر مرتفعة
الزخم
63
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
نطاق اليوم
السعر الحالي 3.99 US$
نطاق 52 أسبوعًا
السعر الحالي 3.99 US$
النتائج المعلنة مع توقعات الإجماع المتاحة.
النتائج المعلنة مع توقعات الإجماع المتاحة.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
ARK Genomic Revolution ETFARKG27.66 مليون1.35%1.56 مليار USD0.75%51.30 US$+4.08%
State Street SPDR S&P Biotech ETFXBI13.13 مليون0.13%9.87 مليار USD0.35%153.77 US$+3.00%
Vanguard Morningstar Total Stock Market ETFVTI11.2 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM8.87 مليون0.01%78.27 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF4.74 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
iShares Russell 2000 Growth ETFIWO2.73 مليون0.02%13.97 مليار USD0.24%356.78 US$+0.94%
iShares Biotechnology ETFIBB2.63 مليون0.03%10.28 مليار USD0.44%206.49 US$+3.00%
Schwab U.S. Small-Cap ETFSCHA2.27 مليون0.01%21.82 مليار USD0.03%32.79 US$+0.40%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
